MX354325B - Método para preparar conjugados glucïdicos de glicopéptidos antigénicos múltiples. - Google Patents

Método para preparar conjugados glucïdicos de glicopéptidos antigénicos múltiples.

Info

Publication number
MX354325B
MX354325B MX2013010618A MX2013010618A MX354325B MX 354325 B MX354325 B MX 354325B MX 2013010618 A MX2013010618 A MX 2013010618A MX 2013010618 A MX2013010618 A MX 2013010618A MX 354325 B MX354325 B MX 354325B
Authority
MX
Mexico
Prior art keywords
multiple antigen
preparing multiple
carbohydrate conjugates
antigen glycopeptide
glycopeptide carbohydrate
Prior art date
Application number
MX2013010618A
Other languages
English (en)
Other versions
MX2013010618A (es
Inventor
Bay Sylvie
Leclerc Claude
Lo-Man Richard
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of MX2013010618A publication Critical patent/MX2013010618A/es
Publication of MX354325B publication Critical patent/MX354325B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Container Filling Or Packaging Operations (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un método para preparar conjugado glucídico de epitope de célula T de la fórmula (I): M(T-B)n (I). Un conjugado glucídico de epitope de célula T de la fórmula (II) M(T-BPr)n.
MX2013010618A 2011-03-17 2012-03-16 Método para preparar conjugados glucïdicos de glicopéptidos antigénicos múltiples. MX354325B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11290138A EP2500033A1 (en) 2011-03-17 2011-03-17 Method for preparing muliple antigen glycopeptide carbohydrate conjugates
PCT/IB2012/051285 WO2012123926A1 (en) 2011-03-17 2012-03-16 Method for preparing multiple antigen glycopeptide carbohydrate conjugates

Publications (2)

Publication Number Publication Date
MX2013010618A MX2013010618A (es) 2014-04-14
MX354325B true MX354325B (es) 2018-02-26

Family

ID=44512239

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010618A MX354325B (es) 2011-03-17 2012-03-16 Método para preparar conjugados glucïdicos de glicopéptidos antigénicos múltiples.

Country Status (16)

Country Link
US (2) US20140378652A9 (es)
EP (2) EP2500033A1 (es)
JP (1) JP6006244B2 (es)
KR (1) KR20140048107A (es)
CN (1) CN103732246B (es)
AU (1) AU2012227940A1 (es)
BR (1) BR112013023599B1 (es)
CA (1) CA2828688C (es)
DK (1) DK2686009T3 (es)
EA (1) EA201391202A1 (es)
ES (1) ES2537180T3 (es)
IL (1) IL228384A0 (es)
MX (1) MX354325B (es)
SG (1) SG193433A1 (es)
WO (1) WO2012123926A1 (es)
ZA (1) ZA201306219B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017134265A1 (en) 2016-02-05 2017-08-10 Institut Pasteur Use of inhibitors of adam12 as adjuvants in tumor therapies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105503A (en) 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
US6410690B1 (en) * 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
DE69834808T2 (de) 1997-03-27 2007-06-06 Institut Pasteur Multiple,kohlenhydrathaltige glycopeptid-antigene, daraus entwickelte impfstoffe sowie deren verwendung
US6676946B2 (en) * 1997-03-27 2004-01-13 Institut Pasteur Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof
EP0996455B1 (en) * 1997-04-16 2009-12-16 Sloan-Kettering Institute For Cancer Research Alpha-o-linked glycoconjugates with clustered (2,6)-st epitopes, methods of preparation and uses thereof

Also Published As

Publication number Publication date
CN103732246A (zh) 2014-04-16
BR112013023599B1 (pt) 2023-01-10
EP2686009B1 (en) 2015-04-29
CA2828688C (en) 2021-08-03
ES2537180T3 (es) 2015-06-03
US20170283466A1 (en) 2017-10-05
EA201391202A1 (ru) 2014-03-31
EP2500033A1 (en) 2012-09-19
US10899799B2 (en) 2021-01-26
US20140171618A1 (en) 2014-06-19
IL228384A0 (en) 2013-12-31
KR20140048107A (ko) 2014-04-23
SG193433A1 (en) 2013-10-30
ZA201306219B (en) 2014-05-28
CA2828688A1 (en) 2012-09-20
EP2686009A1 (en) 2014-01-22
US20140378652A9 (en) 2014-12-25
MX2013010618A (es) 2014-04-14
JP6006244B2 (ja) 2016-10-12
AU2012227940A1 (en) 2013-09-05
DK2686009T3 (da) 2015-06-15
JP2014510083A (ja) 2014-04-24
WO2012123926A1 (en) 2012-09-20
CN103732246B (zh) 2017-06-30
BR112013023599A2 (pt) 2019-05-07

Similar Documents

Publication Publication Date Title
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
MX363512B (es) Proceso de glicoconjugacion.
MX342034B (es) Proteinas monovalentes que se unen a antigenos.
EA201890942A1 (ru) Мультивалентные вакцины с синтетическими наноносителями
PH12014501108A1 (en) Anti-il-36r antibodies
MX2019004378A (es) Edulcorante de estevia altamente soluble.
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
MY162791A (en) Anti-il-23 antibodies
MX340558B (es) Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
MY170720A (en) Antibody formulations
EA201300915A1 (ru) Новый европейский штамм prrsv
SG178886A1 (en) Humanized anti-cdcp1 antibodies
WO2012068317A3 (en) Methods for producing recombinant proteins
MX337203B (es) Novedosas moleculas inhbidoras de jnk.
MX2015011781A (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
UA110128C2 (uk) Індолкарбоксаміди та бензімідазолкарбоксаміди як інсектициди та акарициди
GB201017519D0 (en) Vaccines
EA201300733A1 (ru) Рекомбинантные микобактерии в качестве вакцины
CA2800424C (en) B1,2 cyclic beta glucan compound for use to enhance adaptive immunity by activation of dendritic cells
PH12015501335A1 (en) Immunogenic composition comprising mycoplasma antigens
WO2012021678A3 (en) Isolated bacteria, methods for use, and methods for isolation
PH12014501367A1 (en) Processes for making magnolol and derivatives thereof
AU2012248013B2 (en) Intermediate for synthesizing caspofungin and preparation method therefor
MX354325B (es) Método para preparar conjugados glucïdicos de glicopéptidos antigénicos múltiples.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: INSTITUT PASTEUR

FG Grant or registration